Yosuke Murata

9101193, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Spatial Proximity Between PD-L1(+) Tumor-Associated Macrophages and CD8(+) T Cells Influences Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma.

Spatial Proximity Between PD-L1(+) Tumor-Associated Macrophages and CD8(+) T Cells Influences Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma.

Journal: Cancers
Published: April 05, 2026

Alpha-1B Glycoprotein Is a Novel Hepatocyte-Derived Host Factor Associated with In Vitro Inhibition of HBV Replication and Hepatocellular Carcinoma Progression.

Alpha-1B Glycoprotein Is a Novel Hepatocyte-Derived Host Factor Associated with In Vitro Inhibition of HBV Replication and Hepatocellular Carcinoma Progression.

Journal: Cancers
Published: January 08, 2026

Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.

Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.

Journal: Clinical journal of gastroenterology
Published: October 21, 2025

PD-L1(+) tumor-associated macrophages induce CD8(+) T Cell exhaustion in hepatocellular carcinoma.

PD-L1(+) tumor-associated macrophages induce CD8(+) T Cell exhaustion in hepatocellular carcinoma.

Journal: Neoplasia (New York, N.Y.)
Published: August 31, 2025

Delayed Biliary Hemorrhage due to Pseudoaneurysm Rupture Caused by Migration of Placed Plastic Stent After Endoscopic Ultrasound-Guided Hepaticogastrostomy.

Delayed Biliary Hemorrhage due to Pseudoaneurysm Rupture Caused by Migration of Placed Plastic Stent After Endoscopic Ultrasound-Guided Hepaticogastrostomy.

Journal: DEN open
Published: August 19, 2025

Effective control in MSI-high unresectable intrahepatic cholangiocarcinoma treated with gemcitabine/cisplatin/durvalumab and proton beam therapy: a case report.

Effective control in MSI-high unresectable intrahepatic cholangiocarcinoma treated with gemcitabine/cisplatin/durvalumab and proton beam therapy: a case report.

Journal: Frontiers in immunology
Published: August 14, 2025

Clinical Significance of CD90(+) Circulating Tumor Cells as Dynamic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab and Lenvatinib.

Clinical Significance of CD90(+) Circulating Tumor Cells as Dynamic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab and Lenvatinib.

Journal: Cancers
Published: July 23, 2025

Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA.

Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA.

Journal: Cancers
Published: July 15, 2025

Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors.

Risk factors and long-term prognostic impact of immune related pancreatic injury in patients receiving immune checkpoint inhibitors.

Journal: Frontiers in immunology
Published: March 10, 2025

Influence of antiplatelet drugs on gastric ulcer healing after endoscopic submucosal dissection in patients with early gastric cancer.

Influence of antiplatelet drugs on gastric ulcer healing after endoscopic submucosal dissection in patients with early gastric cancer.

Journal: DEN open
Published: October 23, 2024

Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.

Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.

Journal: Cancers
Published: June 08, 2024

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.

Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.

Journal: Cancers
Published: April 07, 2024
Showing 1-12 of 19

Last Updated: 09/26/2026